How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease DealsSimplywall·Jul 23 at 04:14 AMBCRX-0.43%
BioCryst to Report Second Quarter 2026 Financial Results on August 5Unusual Whales·Jul 22 at 06:58 AMBCRX-0.43%
BioCryst to report Q2 2026 results, host conference call and webcastPUBT·Jul 22 at 06:04 AMBCRX-0.43%
Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?Simplywall·Jul 20 at 08:19 AMBCRX-0.43%
BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officerrttnews·Jul 15 at 06:35 AMBCRX-0.43%
BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In FocusSimplywall·Jul 12 at 08:07 AMBCRX-0.43%
Janney Montgomery Scott LLC Acquires 137,133 Shares of BioCryst Pharmaceuticals, Inc. $BCRXMarket Beat·Jul 11 at 08:29 AMBCRX-0.43%GS-C+7.00%
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goalrttnews·Jul 2 at 09:15 AMNVS-0.72%VRTX+0.90%
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jul 2 at 06:01 AMBCRX-0.43%
BioCryst grants new hires stock options for 33,950 shares at $9.65 eachPUBT·Jul 2 at 06:00 AMBCRX-0.43%
BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy RatingTip Ranks·Jun 30 at 08:35 AMBCRX-0.43%
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga_article·Jun 30 at 08:04 AMBCRX-0.43%EW-1.42%
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price TargetTip Ranks·Jun 29 at 03:55 PMBCRX-0.43%
